LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
|Slideshows|April 4, 2019
- Dermatology Times, April 2019 (Vol. 40, No. 4)
- Volume 40
- Issue 4
6 healthcare issues to watch this year
Author(s)Dermatology Times Staff
PricewaterhouseCoopers believes 2019 is the year a New Health Economy comes of age, according to its 13th annual report, "Top health industry issues of 2019." View the top six takeaways from the report in this slideshow.
Advertisement
PricewaterhouseCoopers believes 2019 is the year a New Health Economy comes of age, according to its 13th annual report, "Top health industry issues of 2019." The company predicts new products, investments and consumer trends will impact healthcare in six key areas.
Articles in this issue
over 7 years ago
The evolution of skin cancerover 7 years ago
The history of aesthetic lasersover 7 years ago
First inductees to Dermatology Hall of Fame announcedover 7 years ago
How to attract loyal patientsover 7 years ago
The study of skin through the centuriesover 7 years ago
Innovation dispatches from the AADover 7 years ago
Tips on treating nail problemsover 7 years ago
Dermatologists as co-conspirators?over 7 years ago
Can I import medications for poorer patients?over 7 years ago
Energy-based therapies for treating GSM disordersAdvertisement
Related to this article
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
Two-year POETYK PsA-2 data showed sustained ACR and minimal disease activity responses with deucravacitinib and no new safety signals.
Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss
2
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
3
Dersimelagon NDA Accepted by FDA with Priority Review for EPP, XLP
4
Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis
5